Cargando…

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation

Co-stimulation is critical to the function of chimeric antigen receptor (CAR) T-cells. Previously, we demonstrated that dual co-stimulation can be effectively harnessed by a parallel (p)CAR architecture in which a CD28-containing second generation CAR is co-expressed with a 4-1BB containing chimeric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halim, Leena, Das, Kushal K., Larcombe-Young, Daniel, Ajina, Adam, Candelli, Andrea, Benjamin, Reuben, Dillon, Richard, Davies, David M., Maher, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863855/ https://www.ncbi.nlm.nih.gov/pubmed/35222427 http://dx.doi.org/10.3389/fimmu.2022.836549

Ejemplares similares

Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors
por: Muliaditan, Tamara, et al.
Publicado: (2021)

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
por: Feucht, J., et al.
Publicado: (2020)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

T Cell Receptor Signaling Can Directly Enhance the Avidity of CD28 Ligand Binding
por: Sanchez-Lockhart, Mariano, et al.
Publicado: (2014)

Generation of human parallel chimeric antigen receptor (pCAR) T cells to achieve synergistic T cell co-stimulation
por: Larcombe-Young, Daniel, et al.
Publicado: (2022)

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
Publicado: (1991)

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells
por: Dai, Qiang, et al.
Publicado: (2020)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia
por: Wu, Lijuan, et al.
Publicado: (2023)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
por: Condomines, Maud, et al.
Publicado: (2015)

Correction: 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Publicado: (2020)

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities
por: Kaviani, Elina, et al.
Publicado: (2022)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells
por: James, Charlotte A., et al.
Publicado: (2022)

Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells
Publicado: (1992)

CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017)

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
por: Tang, Xiao-Yi, et al.
Publicado: (2016)

Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
por: Pei, Kunlin, et al.
Publicado: (2023)

Receptor Avidity and Costimulation Specify the Intracellular Ca(2+) Signaling Pattern in Cd4(+)Cd8(+) Thymocytes
por: Freedman, Bruce D., et al.
Publicado: (1999)

Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
Publicado: (1993)

Forsythoside A Inhibits BVDV Replication via TRAF2-Dependent CD28–4-1BB Signaling in Bovine PBMCs
por: Song, Quan-Jiang, et al.
Publicado: (2016)

Avidity maturation of memory CD8 T cells is limited by self-antigen expression
por: Turner, Michael J., et al.
Publicado: (2008)

Interferon-γ couples CD8(+) T cell avidity and differentiation during infection
por: Uhl, Lion F. K., et al.
Publicado: (2023)

CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells
por: Nakatsugawa, Munehide, et al.
Publicado: (2016)

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells
por: Hombach, Andreas A., et al.
Publicado: (2012)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
por: Nguyen, Phuong, et al.
Publicado: (2020)

A peptide derived from the intercellular adhesion molecule-2 regulates the avidity of the leukocyte integrins CD11b/CD18 and CD11c/CD18
Publicado: (1995)

CD3(+)CD8(+)CD28(−) T Lymphocytes in Patients with Lupus Nephritis
por: Żabińska, Marcelina, et al.
Publicado: (2016)

CD5 Expression Is Developmentally Regulated By T Cell Receptor (TCR) Signals and TCR Avidity
por: Azzam, Hala S., et al.
Publicado: (1998)

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
por: Ercolini, Anne M., et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_oologfqaqntqkt945m62t6a7kn